1. Introduction {#sec0005}
===============

The novel coronavirus (SARS-CoV2) has caused a growing pandemic and global issue now ([@bib0405]). Cancer patients are at a greater risk of catastrophic outcomes of Coronavirus infectious disease 2019 (COVID-19) because of the older age, immunosuppressive condition and combined comorbidity. Cancer patients may become infected by SARS-CoV2 during chemotherapy or may need to receive chemotherapy after the resolution of their disease and receiving coronavirus treatment ([@bib0365]).

Here we reviewed drug interactions of current covid-19 drugs with antineoplastic agents. Montamat SC et al., said that the risk of drug interactions is higher in cancer patient due to their underlying disease, older age and consumption of multiple medications ([@bib0260]). The current paper is a review of the reported and expected drug interactions of current treatments for COVID-19 and anticancer agents.

2. Mechanisms of interaction {#sec0010}
============================

Drug-drug interactions (DDIs) commonly happen when two drugs with DDIs administered before 4--5 half-lives of one of them ([@bib0170]). DDIs can cause three results: decreased therapeutic effect/adverse effects, enhanced therapeutic effect/adverse effects or a new side effect that does not occur with each drug separately. In pharmacodynamic interaction, both drugs affect the same physiologic pathway ([@bib0050]). This effect can be inhibitory or inducible.

Pharmacokinetic interaction happens when one drug influences other drug's absorption, distribution, metabolism or excretion ([@bib0050]). Drugs may affect the GI motility or PH, serum albumin concentration which can affect another drug absorption or distribution ([@bib0050]). Cytochrome P450 (CYP) with more than 50 isoenzymes is responsible for most of drug metabolism in liver. One drug can stimulate or inhibit its own CYP isoenzyme or other isoenzymes with further influencing the metabolism of other drugs that are metabolized with the same isoenzyme ([@bib0395]). Another site of drug interactions occurs at P-glycoprotein that plays an important role in transporting drugs into cell on the cell membrane ([@bib0050]; [@bib0395]).

3. Common therapeutic regiments for COVID-19 {#sec0015}
============================================

The most common proposed treatments for COVID-19 include chloroquine and hydroxychloroquine, azatinavir/ritonavir, lopinavir/ritonavir, remdesivir, tocilizumab and favipiravir ([@bib0010], [@bib0015]; [@bib0070]; [@bib0110]; [@bib0160]).

3.1. Chloroquine {#sec0020}
----------------

Chloroquine (CQ) and hydroxychloroquine (HCQ) are both 4-aminoquinoline agents that historically known as antimalaria drug from 1940s ([@bib0360]). These drugs have been used for treatment of rheumatoid arthritis, lupus erythematous, AIDS and recently COVID-19 ([@bib0170]; [@bib0345]). Additionally, there are several in vivo and in vitro studies that confirm the anticancer effect of both CQ and HCQ. The most prominent evidences are three phase 3 clinical trials that used CQ during glioblastoma multiform with carmustin or temozolomide and showed positive results with added CQ. There are other phase 1--2 trials of addition the CQ to other chemotherapy regimens with hopeful results ([@bib0235]).Terminal elimination half-life of CQ is about 1--2 months and of 50 days for HCQ ([@bib0360]).

Short term use of CQ and HCQ is rarely associated with major side effects but serious side effects such as cardiomyopathy, irreversible retinopathy, myelosuppression and hypoglycemia have been reported after long-term use ([@bib0360]). Among the most serious adverse effects are cardiac side-effects such as atrioventricular block, bundle branch block, cardiac arrhythmia, cardiac failure, cardiomyopathy, electrocardiographic (ECG) changes including flattened T wave, T wave inversion, prolonged QT interval, widened QRS complex, hypotension, torsade's de pointes, ventricular fibrillation and ventricular tachycardia ([@bib0270]).

Tamoxifen, an antiestrogen agent, is administered for breast cancer patients who needs to take it for years ([@bib0305]). CQ decrease the level of tamoxifen by CYP2D6 inhibition effect ([@bib0050]; [@bib0240]). Whether consuming concurrent CQ or HCQ could affect the efficacy of tamoxifen in breast cancer patients is not clear but should be considered.

With regard to anti emetic drugs physicians should be noted that, granisetron is a safe antiemetic agent to be used concurrently with HCQ or CQ because unlike ondansetron, it does not appear to affect any CYP isoenzyme ([@bib0050]).

Ado-Trastuzumab Emtansine (TDM1) that is used to treat HER2-positive metastatic breast cancer, also metabolized largely by CYP3A4 but don't have any effect on this enzyme. ([@bib0020]) We summarized main interactions of this drug with anticancer medicines ([Table1](#tbl0005){ref-type="table"} ).Table 1Chloroquine DDIs:Table 1Covid-19 drugType of interactionResultChloroquineQ-T interval prolongationApalutamide, Leuprolide, Goserelin, Triptorelin,([@bib0145])Increase Q-T prolongation probabilityEribulin ([@bib0285]), Ribociclib ([@bib0350]), Inotuzumab ([@bib0195]), Gemtuzumab ([@bib0330]), Lenvatinib([@bib0130]), Dasatinib ([@bib0190]), Nilotinib ([@bib0205]), Cabozantinib and Ceritinib ([@bib0335]), Methadone ([@bib0030]) Oxaliplatin([@bib0080])Ondansetron([@bib0085])CYP3A4 induceApalutamide([@bib0280]), Ivosidenib ([@bib0280]), Fedratinib(Xu)Decrease the level of CQDabrafenib([@bib0025]), Encorafenib([@bib0025])CYP3A4 inhibitIdelalisib([@bib0025]), Crizotinib([@bib0125]), Fedratinib([@bib0375]), Dasatinib([@bib0165]), Abiraterone([@bib0040]), Bicalutamide([@bib0255]), Aprepitant([@bib0225]), Imatinib([@bib0225])Increase the level of CQCYP2D6 inducers\-\-\--CYP2D6 inhibitorsDacomitinib([@bib0035]), Abiraterone([@bib0380]), Ondansetron([@bib0050]), Methadone([@bib0370])Increase the level of QCPharmacodynamic synergismAll chemotherapy agentsMyelosuppressionPharmacodynamic antagonismSipuleucel-T([@bib0100]; [@bib0300])Effect on distributionMTX([@bib0050])

3.2. Protease inhibitors {#sec0025}
------------------------

Protease inhibitors (PIs) such as atazanavir, ritonavir, lopinavir have been for treatment of COVID-19 (Baden, Lindsey R. and Rubin, Eric J., 2020). Lopinavir is used in combination with ritonavir- Kaletra- to increase the lopinavir's bioavailability ([@bib0120]). Reported half of lopinavir/ritonavir and atazanavir/ritonavir are 2--7/3−4 h, 8--9/5−6 h, respectively ([@bib0055]; [@bib0075]). About 85--95 % of these drugs bind to plasma proteins and metabolized in liver mainly by CYP3A4 isoenzyme ([@bib0230]). Lopinavir is metabolized by CYP3A4 and on the other hand ritonavir is a potent inhibitor of CYP3A4, so the coadministration of them leads an increase in the effect of lopinavir; therefore, lopinavir is not used alone ([@bib0045]; [@bib0230]; [@bib0315]).

Atazanavir, lopinavir/ritonavir also associated with Q-T interval prolongation so should be prescribed with caution with drugs with the same side effect such as tamoxifen, anthracyclines, dasatninb, lapatinib, nilotinib and sunitinib ([Table 2](#tbl0010){ref-type="table"} ) ([@bib0195]) ([@bib0105]; [@bib0180]; [@bib0215]; [@bib0295]).Table 2Protease inhibitors DDIs:Table 2Covid-19 drugType of interactionResultProtease inhibitors[\*](#tblfn0005){ref-type="table-fn"} ([@bib0230]; [@bib0275]; [@bib0315])\--PlatinumNo effectInhibition of CYP3A4TaxansIncrease the level of docetaxelInhibition of CYP3A4VincaalkaloidsIncrease the level vincaalkaloids\--GemcitabineNo effect\--TopotecanNo effectInhibition of CYP3A4IrinotecanIncrease the level of irinotecan\--PemetrexedNo effect\--BevacizumabNo effect\--CetuximabNo effectInhibition of CYP3A4ErlotinibIncrease the level of erlotinibInhibition of CYP3A4GefitinibIncrease the level of gefitinibInhibition of CYP3A4EtoposideExpect to increase the etoposide toxicity\--AnthracyclineNo effectInhibition of CYP3A4EverolimusIncrease the level of Everolimus[^1]

3.3. Favipiravir {#sec0030}
----------------

Favipiravir is a pyrazine analog, originally made in Japan, oseltamivir resistant influenza ([@bib0140]). The drug inhibits RNA-dependent RNA polymerase enzymes leading to prevention of virus replication ([@bib0135]). The elimination half-life is about 2--5.5  with a protein binding of 54 % in plasma and metabolized by aldehyde oxidase (AO) and xanthine oxidase to its metabolite, T705M1, in liver and excreted to urine.([@bib0115]) Dose adjustment based on hepatic impairment is not needed however there is not enough humanized study about it ([@bib0115]). The proposed dose for COVID-19 is the loading dose of 3200 mg on day 1 and maintenance dose of 1200 mg on day 2−14 ([@bib0115]). Main side effects of favipiravir include mild to moderate diarrhea, elevated liver enzymes, testicular toxicity, increased blood uric acid and decrease in neutrophil count [@bib0290]. The rate of Q-T prolongation is low (8%) [@bib0290]. There is limited clinical data about DDIs and metabolism of favipiravir. In vivo study showed inhibitory effect of favipiravir on CYP2C8 isoenzyme [@bib0290]. As well as, other study revealed favipiravir inhibits AO ([@bib0115]). So, more caution was necessary when used AO inhibitors such as tamoxifen or CYP2C8 substrates like paclitaxel with favipiravir [@bib0290].

3.4. Ivermectin {#sec0035}
---------------

Ivermectin is a broad spectrum antiparasitic agent that recently reported to have in vivo effect on SARS-CoV2 virus with 98 % elimination rate of virus RNA in or out of cells ([@bib0060]). It is used by oral or subcutaneous route and metabolized in liver by CYP3A4 isoenzyme ([@bib0065]; [@bib0385]). Ivermectin binds to plasma protein by rate of 93 % and is mainly excreted in feces ([@bib0210]). Its half-life based on administration route is around 12−20 hours ([@bib0065]). The absorption, distribution and elimination of ivermectin is dependent on P-glycoprotein, on the other hand, it is a potent inhibitor of P-glycoprotein ([@bib0250]). The main interactions of this drug are caused by its effects on P-glycoprotein. Ivermectin may change the p-glycoprotein ABCB1 substrate ([@bib0250]). The most reported side effects are reported in the context of its use an antiparasitic drug as the result of immunologic response to parasite, including skin rash, fever, headache, nausea and dizziness ([@bib0185]). Drug interaction of Ivermectin and chemotherapy agents is an important issue both in treatment of cancer or COVID-19 ([@bib0065]).

There are not enough clinical data about ivermectin drug interactions. It is reasonable to cautiously administer this drug with drugs that are metabolized by CYP3A4 and induce or inhibit P-glycoproteins ([Table 3](#tbl0015){ref-type="table"} ) ([@bib0175]; [@bib0245]).Table 3Ivermectin DDIs:Table 3Covid-19 drugType of interactionIvermectinP-glycoprotein substratesDoxorubicin ([@bib0200])Mitoxantrone ([@bib0200])Paclitaxel ([@bib0220])Vinblastine ([@bib0220])Vincristine ([@bib0200])Ivermectin ([@bib0220])Lapatinib ([@bib0090])Lenvatinib ([@bib0090])Sorafenib ([@bib0090])Actinomycine D ([@bib0400])Docetaxel ([@bib0400])Imatinib ([@bib0400])Irinotecan ([@bib0400])Mitomycine C ([@bib0400])Topotecan ([@bib0400])P-glycoprotein inhibitorsEtoposide ([@bib0200])Tamoxifen ([@bib0200])Ivermectin ([@bib0250])Methadone ([@bib0200])Vinblastin ([@bib0400])P-glycoprotein inducersCisplatin ([@bib0400])Daunorubicin ([@bib0400])Doxorubicin ([@bib0400])Vinblastine ([@bib0400])Vincristine ([@bib0400])Etoposide ([@bib0400])

3.5. Remdesivir {#sec0040}
---------------

Remdisivir (RDV) is a new investigational antiviral agent, that have been used against coronavirus. RDV inhibits the RNA-dependent RNA polymerase ([@bib0005]; [@bib0150]; [@bib0355]).

Its oral bioavailability is very low, so it is used intravenously ([@bib0245]). Unfortunately, there are not any data about the drug pharmacokinetic and drug-drug interaction. In a phase II trial on remdesivir, 9 cases of side-effects were reported but 8 cases of them were not related to remdesivir ([@bib0355]).

While waiting for more definite evidence, physicians should prescribe this drug with caution in cases of multiple medications.

3.6. Tocilizumab {#sec0045}
----------------

Tocilizumab (TCZ, Actemra) is an Ig G recombinant humanized monoclonal antibody that blocks the receptor of IL-6. TCZ has been used for treatment of rheumatoid arthritis ([@bib0390]). As the result of the cytokine storm the increased level of IL-6 is observed in the course of COVID-19, based on this finding, TCZ is currently used for treatment of this condition ([@bib0095]).

There is no information regarding the metabolism and plasma protein binding of tocilizumab. Its half- life depending on administration dose and routes is 11--13 days ([@bib0155]).

Reported adverse effects are upper respiratory tract infection, neutropenia, headache, hypertension, ALT elevation and lipid profile changes. Mild reaction in infusion site is common ([@bib0265]; [@bib0340]). One study showed that TCZ has no effect on QT interval ([@bib0155]).

Among the drugs that has concurrently used with TCZ, It seems that co-administration of TCZ has no effect on MTX pharmacokinetic ([@bib0325]). Increasing the level of IL-6 is the consequence of blocking IL-6 receptors by TCZ. Elevated IL-6 reduces CYP450 activity, TCZ may reverse this reduced activity of CYPA50. This issue must be kept in mind when we want to administer TCZ with other agents that metabolized by CYP450 ([@bib0320]). TCZ is an immunosuppressive agent; therefore, there is a concern toward its administration in cancer patients who are already immunosuppressed as the result of chemotherapy. It should also be noted that due to the long half-life of TCZ monitoring of this interaction may be necessary for 1--2 months after the discontinuation of TCZ ([@bib0310]).

4. Conclusion {#sec0050}
=============

In conclusion, there are limited data about the metabolism or drug interactions some of the current COVID-19 treatments. But some of them have been studied more. Knowing of the metabolism, half-life and drug interactions of the current covid-19 treatments help physicians to make a better and quick decisions and manage correctly.
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[^1]: It should be mentioned that hyperbilirubinemia can be seen with atazanavir, but is not a guidance for chemotherapy drug adjustment dose ([@bib0315]).
